echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Zhong Nanshan guided the team to build the first non-GMO mouse model of new coronary pneumonia

    Zhong Nanshan guided the team to build the first non-GMO mouse model of new coronary pneumonia

    • Last Update: 2020-11-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    new coronavirus SARS-CoV-2 intrusion intotrusion is human angiotensin-converting enzyme 2 (hACE2), while mouse entogeneic subject mouse ACE2 cannot mediate virus invasion due to differences in amino acid key points. Early in the epidemic, although China's strains have been isolated, but due to the limited number of international and domestic hACE2
    mice, breeding time is long, clinical symptoms are not typical, resulting in China's COVID-19 pneumonia diagnosis and treatment program, drugs, vaccines and disease-causing mechanisms in vivo verification serious lag.
    June 10, under the guidance of Zhong Nanshan
    , the team of Professor Zhao Jinxuan of the First Hospital/National Key Laboratory for Respiratory Diseases affiliated with Guangzhou Medical University worked with the National Biosecurity Testing Key Laboratory (P3 Laboratory) of Guangzhou Customs Technology Center, the University of Iowa, Guangzhou Regenerative Medicine and Health Guangdong Province Laboratory, China
    Guangzhou Institute of Biomedicine and Health, and other teams, online in Cell Magazine. The results of the study, entitled General of a Broadly Useful Model for COVID-19 Pathogenesis Vaccination, and Treatment, were published, and the first non-
    mouse model of new coronary pneumonia was rapidly established using adenovirus transductive mice expressing the new coronavirus subject ACE2, which can be applied to the evaluation of the effects of new coronary drugs, vaccine effectiveness testing, and new coronary pathogenic mechanisms.In this study, the team used adenovirus vectors to transduce hACE2 in mice, successfully solving these scientific challenges and establishing the first international model of non-
    new crown pneumonia mice (see Figure 1). After SARS-CoV-2 infection in mice, high-titration neocycvirus can be detected in the lungs, with a virus titration of up to 107 PFU per grams of tissue, and clinical pathological manifestations of weight loss and similar neocyclind patients.Animal Model Pattern Map
    further, by comparing wild mice with mice with type I interferon-controlled mice and interferon pathline key gene STAT1 knocked out differences in mice after the new coronavirus infection, and found that type I interferon played a protective role in the new coronavirus infection. In addition, in this model, the new coronavirus infection can induce the body to produce strong virus-specific T-cell response and body fluid immune response. More importantly, the team used this mouse model to evaluate the therapeutic effects of plasma and redsivir on new coronavirus infections in new coronary infections. The results showed that the pulmonary virus titration was significantly reduced in mice given plasma therapy and the drug group, and the pathological damage was reduced (see Figure 2).2. In the plasma and Redsivir treatment groups of patients who had transferred the new crown, the titration of the pulmonary virus decreased in mice and the pathological damage to the lungs decreased.
    Compared with the traditional subject
    mouse model, this model has a short construction period (2-3 weeks), does not need special breeding, can be used for a variety of genetic modification mouse animal model construction, and the technical method is simple, easy to repeat, suitable for large-scale promotion, is conducive to China's antiviral drugs, antibodies, vaccine emergency verification and disease mechanism research, and has been widely shared with many units in China, effectively alleviated the lack of COVID-19 pneumonia animal model in China.
    , Professors David Zhao are understood to have studied Lead Contact, Stanley Perlman and Paul B. McCray of the University of Iowa. Professor Jr is the co-author of this paper, Dr. Sun Jing, Dr. Zhuang Zhen, Dr. Liu Donglan, Dr. Zhu Airu, Dr. Zhao Jingxian, Dr. Xi Wei, Dr. Zheng Jian, Dr. Li Wei, Dr. Roy Lok-Yin Wong, Dr. Huang Jicheng, Dr. Li Xiaobo, Guangzhou Customs Technology Center, and Dr. He Jiangping, Guangzhou Regenerative Medicine and Health Guangdong Province.
    note that researchers from the University of Washington School of Medicine and others published similar findings back-to-back in cell magazine.
    full text link:

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.